betamethasone/calcipotriol (BFH 772) / Novartis - LARVOL DELTA

Drug repositioning for rosacea disease: Biological TARGET identification, molecular docking, pharmacophore mapping, and molecular dynamics analysis. (PubMed, Comput Biol Med) - "Furthermore, considering the drugs currently used for rosacea management, we demonstrated stable interactions between isotretinoin and BFH772 with SKAP2, and permethrin and PAC-14028 with S100A7A. Similarly, considering drugs targeting SKAP2 and S100A7A interactome proteins, we found that pitavastatin and dasatinib exert stable interactions with SKAP2, and lovastatin and tirbanibulin with S100A7A...In conclusion, our study provides evidence for the possible contribution of SKAP2 and S100A7A to rosacea pathology. Furthermore, it provides significant information on the molecular interactions between drugs and these proteins, highlighting the importance of considering structural features and binding interactions in the design of targeted therapies for skin disorders such as rosacea."

Journal • Dermatology • Dermatopathology • Rosacea • SKAP2

Calcipotriol/Betamethasone Dipropionate for the Treatment of Psoriasis: Mechanism of Action and Evidence of Efficacy and Safety versus Topical Corticosteroids. (PubMed, J Clin Med) - "The combination therapy rapid onset of action, coupled with a simplified dosing regimen, has been identified as crucial for improving long-term adherence and patient outcomes. In conclusion, Cal/BDP is confirmed as a versatile, effective, and convenient option for the patient in psoriasis management."

Clinical • Journal • Review • Dermatology • Immunology • Psoriasis

Pustular psoriasis following COVID-19: successful bimekizumab treatment. (EADV-Sp 2024) - "He was on risankizumab and had previously received topical betamethasone/calcipotriol, UVB phototherapy, acitretin and apremilast. Despite the need for further evidence, the significant and rapid improvement of these patients suggests that bimekizumab may have an important role in the management of pustular psoriasis."

Atrial Fibrillation • Cardiovascular • Chronic Obstructive Pulmonary Disease • Coronary Artery Disease • Cough • Dermatology • Diabetes • Heart Failure • Hypertension • Immunology • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Psoriasis • Pulmonary Disease • Pustular Psoriasis • Respiratory Diseases

A case of IgA pemphigus in a patient with a history of psoriasis (EADV 2023) - "A year ago, he was diagnosed with psoriasis at another hospital and was undergoing oral cyclosporine, topical betamethasone/calcipotriol and tacrolimus treatment. Dermatologists managing patients with psoriasis should be aware of this epidemiological feature that bullous diseases can be associated with psoriasis, and prospective studies are required to further delineate their relation."

Clinical • Dermatology • Dermatopathology • Immunology • Inflammation • Psoriasis

Cost-Effectiveness Analysis of Halobetasol and Tazarotene (DUOBRIITM) Compared to Standard of Care for Adult Patients with Moderate-to-Severe Plaque Psoriasis in Québec (ISPOR 2023) - "The SoC (betamethasone/calcipotriol [BD/VDA] followed by [>] systemic therapy [ST]; [BD/VDA>ST]) was compared to HP/TAZ>ST. Considering the chronic nature of plaque psoriasis, adding HP/TAZ to SoC would lead to considerable long-term savings in Quebec while improving population health."

Clinical • Cost effectiveness • HEOR • Dermatology • Immunology • Psoriasis

Fractional CO2 Laser versus Fractional CO2 Laser Plus Betamethasone/Calcipotriol Ointment in the Treatment of Nail Psoriasis. (PubMed, Dermatol Surg) - "Fractional CO2 laser can be an effective and promising new treatment for nail psoriasis."

Journal • Dermatology • Immunology • Psoriasis

Prospective Observational Evaluation of Fixed Combination Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in the Management of Psoriasis with Scalp Involvement in Everyday Clinical Practice (the CAPITIS Study). (PubMed, Dermatology) - "This study demonstrated the effectiveness, rapid onset of action, good tolerability, and good safety profile of the Cal/BD aerosol foam in patients with scalp psoriasis treated in a real-world setting."

Clinical • Journal • Observational data • Dermatology • Immunology • Pruritus • Psoriasis

Efficacy of Calcipotriol/Betamethasone Dipropionate Fixed-Combination Aerosol Foam in the Treatment of Localized Scalp Psoriasis: A Real-Life Case Series from Switzerland. (PubMed, Dermatol Ther (Heidelb)) - "Our case series confirms that Cal/BD foam is a rapid, effective, and convenient treatment for localized scalp psoriasis in a nonselected real-world patient cohort refractory to TCS or other local treatments. Clear application instructions are crucial for treatment success and cosmetic acceptance, however."

Journal • Dermatology • Immunology • Psoriasis

Sub-population analysis of patients with plaque psoriasis treated with calcipotriol/betamethasone aerosol foam; effectiveness and patient satisfaction, according to baseline disease severity and prior psoriasis treatment experience, in a Greek population. (PubMed, Dermatol Ther) - "Reduction from baseline in psoriasis symptoms was observed in all patient groups. The greatest reductions were observed in treatment-naïve patients with severe disease. Clinically relevant benefits were observed with Cal/BD aerosol foam in psoriasis patients, regardless of prior treatment-experience and disease severity at baseline."

Journal • Dermatology • Immunology • Psoriasis

Pulse-Dye Laser Followed by Betamethasone-Calcipotriol and Fractional Ablative CO2-Laser-Assisted Delivery for Nail Psoriasis. (PubMed, Dermatol Surg) - "Combined PDL and fractional ablative CO2-LADD of betamethasone-calcipotriol gel should be considered for the treatment of nail psoriasis."

Journal • Dermatology • Immunology • Pain • Psoriasis

Paradoxical psoriasis caused by tumour necrosis factor-a inhibitor therapy: a report of seven cases from a single centre (BAD 2017) - "...We report seven patients (four female, three male, aged 34–43 years) who developed paradoxical psoriasis following treatment with TNFi therapy: adalimumab (n = 3), infliximab (n = 2) and certolizumab (n = 2)...One patient, who developed paradoxical plaque psoriasis secondary to infliximab, was able to remain on this drug and was managed topically with betamethasone/calcipotriol with good control. However, topical therapies (including 60% clobetasol with 40% propylene glycol for PPP) had limited efficacy for the remaining six patients and subsequently the causative TNFi was stopped...Two patients were commenced on ustekinumab and improvement was observed after 10–12 weeks...To our knowledge little is known about the mechanism underlying its development; however, it has been postulated that upregulation of interferon secondary to TNF-a blockade could be contributory. Therefore, switching to a biological therapy with an alternate mechanism of action may be beneficial."

Clinical • Ankylosing Spondylitis • Biosimilar • Immunology • Inflammatory Bowel Disease • Ophthalmology • Psoriasis • Sarcoidosis

Efficacy of Calcipotriol-Betamethasone Ointment in Patients with Mild to Moderate Plaque Psoriasis: Subgroup Analyses. (PubMed, Dermatology) - "Increased BMI and obesity present risk factors for reduced treatment effectiveness. Importantly, the efficacy of calcipotriol-betamethasone ointment was consistent in all subgroups."

Clinical • Journal

Patient and Physician Satisfaction with Calcipotriol and Betamethasone Dipropionate Aerosol Foam in the Treatment of Plaque Psoriasis on the Body. (PubMed, Actas Dermosifiliogr) - "Both patients and physicians expressed high satisfaction with the use of Cal/BD aerosol foam for the treatment of plaque psoriasis on the body."

Clinical • Journal

Sensitivity of Different In Vitro Performance Tests and Their In Vivo Relevance for Calcipotriol/Betamethasone Ointment. (PubMed, Pharm Res) - "The results of in vitro experiments rank orderly correlated with the results of clinical study. In vitro methods are more sensitive and highly discriminatory when compared to in vivo performance."

Journal • Preclinical

Differential effects of phototherapy, adalimumab and betamethasone/calcipotriol on effector and regulatory T cells in psoriasis. (PubMed, Br J Dermatol) - "The differential effects reported here for the above-mentioned treatment modalities could be exploited to optimize or design therapeutic strategies to better overcome the inflammatory drivers and restore the Th17/Treg balance in psoriasis."

Journal • Preclinical